AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 mg Or 30 mg) In Patients With Moderate-to-severe Atopic Dermatitis
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced results from a new post-hoc analysis of the Measure Up 1 and Measure Up 2 Phase 3 studies of Upadacitinib in patients with moderate-to-severe atopic dermatitis. The analysis provides insights into the efficacy of Upadacitinib at 15 mg and 30 mg doses.
September 25, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's new post-hoc analysis from Phase 3 studies of Upadacitinib shows promising results for treating moderate-to-severe atopic dermatitis, potentially boosting investor confidence in the drug's market potential.
The announcement of positive results from a post-hoc analysis of Phase 3 studies for Upadacitinib could enhance investor confidence in the drug's efficacy and market potential, likely leading to a positive short-term impact on AbbVie's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90